Encounter frequency and blood pressure in hypertensive patients with diabetes mellitus

Hypertension

Volumn 56, Issue 1, 2010, Pages 68-74

  Turchin, Alexander ^a,b,c   Goldberg, Saveli I ^d   Shubina, Maria ^a   Einbinder, Jonathan S ^a,b,c   Conlin, Paul R ^a,b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PARTNERS HEALTHCARE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Encounter frequency; Hypertension; Outcomes; Visit frequency

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOCTOR PATIENT RELATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OFFICE VISITS; PHYSICIAN-PATIENT RELATIONS; PRIMARY HEALTH CARE; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 77953809255     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.148791     Document Type: Article

References (51)

1. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156-163.
2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-828.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16: 434-444.
4. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parving HH. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ. 2004;328:1105.
5. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321: 412-419.
6. Hypertension in Diabetes Study (HDS): II-increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens. 1993;11:319-325.
7. Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-840.
8. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762 (Pubitemid 28269185)
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
10. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Oph-thalmol. 2004;122:1631-1640.
11. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-1097.
12. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J, for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihy-pertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276: 1886-1892
13. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ. 1998;317:720-726
14. CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542-2551.
15. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531-537.
16. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med. 2002;136:565-574.
17. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337-442.
18. Jones DW, Hall JE. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension. 2004;43:1-3.
19. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957-1963.
20. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47: 345-351.
21. Lichtenstein MJ, Sweetnam PM, Elwood PC. Visit frequency for controlled essential hypertension: general practitioners' opinions. J Fam Pract. 1986;23:331-336.
22. Lichtenstein MJ, Steele MA, Hoehn TP, Bulpitt CJ, Coles EC. Visit frequency for essential hypertension: observed associations. J Fam Pract. 1989;28:667-672.
23. Guthmann R, Davis N, Brown M, Elizondo J. Visit frequency and hypertension. J Clin Hypertens (Greenwich). 2005;7:327-332.
24. Parchman ML, Bisonni RS, Lawler FH. Hypertension management: relationship between visit interval and control. Fam Pract Res J. 1993;13: 225-231.
25. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
26. Turchin A, Kohane IS, Pendergrass ML. Identification of patients with diabetes from the text of physician notes in the electronic medical record. Diabetes Care. 2005;28:1794-1795.
27. Turchin A, Shubina M, Breydo E, Pendergrass ML, Einbinder JS. Comparison of information content of structured and narrative text data sources on the example of medication intensification. J Am Med Inform Assoc. 2009;16:362-370.
28. Turchin A, Shubina M, Chodos AH, Einbinder JS, Pendergrass ML. Effect of board certification on antihypertensive treatment intensification in patients with diabetes mellitus. Circulation. 2008;117:623-628.
29. Turchin A, Kolatkar NS, Grant RW, Makhni EC, Pendergrass ML, Einbinder JS. Using regular expressions to abstract blood pressure and treatment intensification information from the text of physician notes. J Am Med Inform Assoc. 2006;13:691-695.
30. Lin DY. Cox regression analysis of multivariate failure time data: the marginal approach. Stat Med. 1994;13:2233-2247.
31. Greenland S. Principles of multilevel modelling. Int J Epidemiol. 2000; 29:158-167.
32. Berlowitz DR, Ash AS, Hickey EC, Glickman M, Friedman R, Kader B. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care. 2003;26:355-359.
33. Chapko MK, Fisher ES, Welch HG. When should this patient be seen again? Eff Clin Pract. 1999;2:37-43.
34. Ward MM. Rheumatology visit frequency and changes in functional disability and pain in patients with rheumatoid arthritis. J Rheumatol. 1997;24:35-42.
35. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
36. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Bohm M, Williams B, Pogue J, Koon T, Yusuf S. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial Study. J Hypertens. 2009;27:1360-1369.
37. Patel NC, Crismon ML, Miller AL, Johnsrud MT. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy. 2005;25:1242-1247.
38. Plantinga LC, Fink NE, Sadler JH, Levey AS, Levin NW, Rubin HR, Coresh J, Klag MJ, Powe NR. Frequency of patient-physician contact and patient outcomes in hemodialysis care. J Am Soc Nephrol. 2004;15: 210-218.
39. Schwartz LM, Woloshin S, Wasson JH, Renfrew RA, Welch HG. Setting the revisit interval in primary care. J Gen Intern Med. 1999;14:230-235.
40. DeSalvo KB, Bowdish BE, Alper AS, Grossman DM, Merrill WW. Physician practice variation in assignment of return interval. Arch Intern Med. 2000;160:205-208.
41. Hauer KE, Durning SJ, Kernan WN, Fagan MJ, Mintz M, O'Sullivan PS, Battistone M, DeFer T, Elnicki M, Harrell H, Reddy S, Boscardin CK, Schwartz MD. Factors associated with medical students' career choices regarding internal medicine. JAMA. 2008;300:1154-1164.
42. Bodenheimer T. Primary care-will it survive? N Engl J Med. 2006;355: 861-864.
43. Ostbye T, Yarnall KS, Krause KM, Pollak KI, Gradison M, Michener JL. Is there time for management of patients with chronic diseases in primary care? Ann Fam Med. 2005;3:209-214.
44. Wick A, Koller MT. Views of patients and physicians on follow-up visits. Swiss Med Wkly. 2005;135:139-144.
45. Okie S. Innovation in primary care-staying one step ahead of burnout. N Engl J Med. 2008;359:2305-2309.
46. Lee TH, Bodenheimer T, Goroll AH, Starfield B, Treadway K. Perspective roundtable: redesigning primary care. N Engl J Med. 2008; 359:e24.
47. New JP, Mason JM, Freemantle N, Teasdale S, Wong LM, Bruce NJ, Burns JA, Gibson JM. Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trial. Diabetes Care. 2003;26:2250-2255.
48. Taylor CB, Miller NH, Reilly KR, Greenwald G, Cunning D, Deeter A, Abascal L. Evaluation of a nurse-care management system to improve outcomes in patients with complicated diabetes. Diabetes Care. 2003;26: 1058-1063.
49. Denver EA, Barnard M, Woolfson RG, Earle KA. Management of uncontrolled hypertension in a nurse-led clinic compared with conventional care for patients with type 2 diabetes. Diabetes Care. 2003;26: 2256-2260.
50. Schectman G, Barnas G, Laud P, Cantwell L, Horton M, Zarling EJ. Prolonging the return visit interval in primary care. Am J Med. 2005;118: 393-399.
51. Linder JA, Rigotti NA, Schneider LI, Kelley JH, Brawarsky P, Haas JS. An electronic health record-based intervention to improve tobacco treatment in primary care: a cluster-randomized controlled trial. Arch Intern Med. 2009;169:781-787.